SCM
DAWN

Silverarc Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Silverarc Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-105,476
Closed -$1.89M – 86
2022
Q2 		$1.89M Buy
+105,476
New +$1.09M 0.58% 43

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silverarc Capital Management's DAWN Position: Q3 2022 in Review

Silverarc Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q3 2022, closing a stake of 105,476 shares — an estimated $1.89M sold.

Silverarc Capital Management first reported a position in DAWN in Q2 2022 and held it in 1 quarter. The position peaked at $1.89M in Q2 2022. 93 funds tracked by Wall St. Rank hold DAWN as of Q3 2022.

  • Silverarc Capital Management reported no remaining Day One Biopharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Silverarc Capital Management sold 105,476 Day One Biopharmaceuticals shares in Q3 2022, an estimated $1.89M.
  • Silverarc Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Silverarc Capital Management's Day One Biopharmaceuticals position peaked at $1.89M in Q2 2022.
  • 93 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2022.

Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.